Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033
Lynparza tablets are indicated in combination with bevacizumab for the maintenance treatment of patients with advanced HRD-positive ovarian cancer.1
HRD=homologous recombination deficiency.
1. Lynparza (olaparib). Summary of Product Characteristics. July 2025.
This promotional material has been fully funded and developed by AstraZeneca and MSD
For UK healthcare professionals only.
Click here for UK Prescribing Information.
GB-68473 | September 2025
Lynparza tablets are indicated in combination with bevacizumab for the maintenance treatment of patients with advanced HRD-positive ovarian cancer.2
ESGO=European Society of Gynaecological Oncology; ESMO=European Society for Medical Oncology; ESP=European Society of Pathology; HRD=homologous recombination deficiency.
1. Ledermann J, et al. Ann Oncol. 2024;35:248–266; 2. Lynparza (olaparib). Summary of Product Characteristics. July 2025.
For UK healthcare professionals only. Adverse event reporting can be found on the first frame of this banner.
Click here for UK Prescribing Information.
GB-68473 | September 2025
For UK healthcare professionals only
Ovarian Cancer Academy:
From Patient to Practice
CPD-certified webinar
These promotional events have been organised and funded by MSD
and AstraZeneca.
For UK healthcare professionals only.
MSD and AstraZeneca products will be discussed at these meetings. Please consult the Summary of Product Characteristics for further information to minimise the risks associated with the use of these medicines before prescribing.
(a)OC=(advanced) ovarian cancer; CPD=Continuing Professional Development.
Adverse event reporting can be found on the first frame of this banner.
Click here for UK Prescribing Information.
GB-68473 | September 2025
This link will take you to an MSD and AstraZeneca promotional website
where products will be mentioned.